Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Dec 25;33(2):129–136. doi: 10.1177/1945892418815615

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2018

PMC Copyright notice

Figure 3. — Enhanced antibacterial activity of ciprofloxacin against Pseudomonas aeruginosa PAO-1 in combination with different ivacaftor concentrations. Antibacterial effects of ciprofloxacin and ivacaftor were noticed at the 0.02 µg/mL and 0.05 µg/mL concentrations of ciprofloxacin with 8 and 16 µg/mL of ivacaftor. Two-way ANOVA demonstrated a statistically significant synergism between ciprofloxacin and 16 µg/mL of ivacaftor (P < .0001). Asterisk represents significance of each ciprofloxacin group compared to its respective control group (P < .05, 1-way ANOVA and Tukey’s test). Three different concentrations of ciprofloxacin were used: 0.01, 0.02, and 0.05 µg/mL. Within the same ciprofloxacin group, a statistical difference with P < .05 among different ivacaftor groups was marked by a #. NS means no statistical significance. All groups consisted of at least 4 experiments.